article Open AccessTop 1% cited
Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents
Leukemia · 2013 · Vol. 28(6) · pp. 1280–1288
Hui Yang✉(The University of Texas MD Anderson Cancer Center)Carlos E. Bueso‐Ramos(The University of Texas MD Anderson Cancer Center)Courtney DiNardo(The University of Texas MD Anderson Cancer Center)Marcos R. EstecioMasoud Davanlou(The University of Texas MD Anderson Cancer Center)Qi-Rong GengZhihong Fang(The University of Texas MD Anderson Cancer Center)Martin Nguyen(The University of Texas MD Anderson Cancer Center)Sherry Pierce(The University of Texas MD Anderson Cancer Center)Yue Wei(The University of Texas MD Anderson Cancer Center)Simrit Parmar(The University of Texas MD Anderson Cancer Center)Jörge E. Cortes(The University of Texas MD Anderson Cancer Center)Hagop Kantarjian(The University of Texas MD Anderson Cancer Center)Guillermo Garcia‐Manero(The University of Texas MD Anderson Cancer Center)
Acute Myeloid Leukemia ResearchImmune cells in cancerCancer Immunotherapy and BiomarkersDecitabineMyeloid leukemiaMyelodysplastic syndromesLeukemiaChronic myelomonocytic leukemiaMedicineAzacitidinePD-L1ImmunologyHypomethylating agent
MeSH terms
DecitabineAdultAgedAged, 80 and overAntimetabolites, AntineoplasticAzacitidineFemaleFlow CytometryHumansImmunoenzyme TechniquesLeukocytes, MononuclearMaleMiddle AgedMyelodysplastic SyndromesPrognosis
Funding
- University of Texas MD Anderson Cancer Center
Citations
675
FWCI
16.35
field-weighted impact
References
39
Percentile
99%
vs. same field & year
Citations per year
References
International Scoring System for Evaluating Prognosis in Myelodysplastic Syndromes
Blood · 1997 · 4,444 citations
Myeloid-derived suppressor cells as regulators of the immune system
Nature reviews. Immunology · 2009 · 6,584 citations
Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape
Science Translational Medicine · 2012 · 2,123 citations
Decitabine improves patient outcomes in myelodysplastic syndromes
Cancer · 2006 · 1,506 citations
Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation
The Journal of Experimental Medicine · 2000 · 5,184 citations
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study
The Lancet Oncology · 2009 · 2,624 citations
PD-1 and Its Ligands in Tolerance and Immunity
Annual Review of Immunology · 2008 · 5,272 citations
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
New England Journal of Medicine · 2012 · 12,531 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.